A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Colorectal Cancer Not MSI-H or MMR-deficient|GIST|Oesophageal or Gastric Carcinoma|Biliary Tract Cancer|Hepatocellular Carcinoma|Soft-tissue Sarcoma|Thyroid Cancer|Gastro-enteropancreatic Neuroendocrine Tumor|Non-small Cell Lung Cancer|Solid Tumor, Adult|Urothelial Carcinoma|HPV-Related Carcinoma|Triple Negative Breast Cancer|Renal Carcinoma|Mesotheliomas Pleural
Interventions: DRUG: Phase 1 : Regorafenib|DRUG: Phase 1 : Avelumab|DRUG: Phase 2 : Regorafenib|DRUG: Phase 2 : Avelumab|DRUG: Phase 2: low-dose Regorafenib
Sponsor: Institut Bergonié
Collaborators: Bayer|Merck KGaA, Darmstadt, Germany